Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TECAS for Mild-to-moderate Depression
NCT03909217Phase 3Completed
- Sponsor
- The University of Hong Kong
- Start
- Jul 2019
- Primary completion
- Jul 2021
- Countries
- 1
01
Overview
Phase 3, randomised, single-blind trial in major depressive disorder (MDD), sponsored by The University of Hong Kong. Primary endpoint: Clinical response at the end of treatment at 8 weeks. Started Jul 2019; status: completed.
02
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT03909217.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03909217.